secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018763
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q4 2023 net loss $83.5M; cash $750M funds into H2 2026
-------------------------------------------------------------------------

- Net loss $83.5M in Q4 2023 ($0.67 per share) vs $67.5M loss in Q4 2022.
- Full year 2023 net loss $342.0M ($2.79 per share) vs $290.5M in 2022.
- Cash, cash equivalents and investments $750.1M at Dec 31, 2023; expected to fund operations into H2 2026.
- Completed enrollment in RLY-2608 600mg + fulvestrant dose expansion; initiated additional cohorts and triplet with ribociclib.
- Deprioritized further clinical development of RLY-5836.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/rlay-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer